# CELGENE CORP /DE/

CELGENE CORP /DE/ is a company headquartered in Summit, NJ, United States.

## Company overview

- **Legal name:** CELGENE CORP /DE/
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Summit, NJ, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000816284

## About

CELGENE CORP /DE/ is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000816284, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2019-02-26, it reported annual revenue of USD 15,281,000,000; net income of USD 4,046,000,000; total assets of USD 35,480,000,000 for the fiscal period ended 2018-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2018 (period ended 2018-12-31)

- **Revenue:** $15.3B (USD 15,281,000,000)
- **Net income:** $4.0B (USD 4,046,000,000)
- **Total assets:** $35.5B (USD 35,480,000,000)
- **Cash and equivalents:** $4.2B (USD 4,234,000,000)
- **Operating cash flow:** $5.2B (USD 5,171,000,000)

### FY2017 (period ended 2017-12-31)

- **Revenue:** $13.0B (USD 13,003,000,000)
- **Net income:** $2.9B (USD 2,940,000,000)
- **Total assets:** $30.1B (USD 30,141,000,000)
- **Cash and equivalents:** $7.0B (USD 7,013,000,000)
- **Operating cash flow:** $5.2B (USD 5,246,000,000)

### FY2016 (period ended 2016-12-31)

- **Revenue:** $11.2B (USD 11,229,200,000)
- **Net income:** $2.0B (USD 1,999,200,000)
- **Total assets:** $28.1B (USD 28,085,600,000)
- **Cash and equivalents:** $6.2B (USD 6,169,900,000)
- **Operating cash flow:** $4.0B (USD 3,976,300,000)
- **Later filings:** Revenue, Net income, Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2015 (period ended 2015-12-31)

- **Revenue:** $9.3B (USD 9,256,000,000)
- **Net income:** $1.6B (USD 1,602,000,000)
- **Total assets:** $27.1B (USD 27,053,400,000)
- **Cash and equivalents:** $4.9B (USD 4,880,300,000)
- **Operating cash flow:** $2.5B (USD 2,483,900,000)
- **Later filings:** Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form SC 13G — filed 2020-02-10 — SC 13G
- Form 8-K — filed 2019-11-22 — period 2019-11-21 — 8-K
- Form 8-K — filed 2019-11-20 — period 2019-11-15 — FORM 8-K
- Form 10-Q — filed 2019-10-31 — period 2019-09-30 — 10-Q
- Form 8-K — filed 2019-10-31 — period 2019-10-31 — FORM 8-K
- Form 8-K — filed 2019-08-26 — period 2019-08-25 — FORM 8-K
- Form 10-Q — filed 2019-07-30 — period 2019-06-30 — 10-Q
- Form 8-K — filed 2019-07-30 — period 2019-07-30 — 8-K
- Form SC 13G — filed 2019-05-30 — SC 13G
- Form 10-Q — filed 2019-04-25 — period 2019-03-31 — 10-Q
- Form 8-K — filed 2019-04-25 — period 2019-04-25 — 8-K
- Form 8-K — filed 2019-04-12 — period 2019-04-12 — FORM 8-K

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/celgene-corp-de

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology